EUPHA section on Utilisation of medecines
Chairperson
Dr Pietro Folino Gallo
Italian Medicines Agency
via della Sierra Nevada, 60
00144 Rome
Italy
Telephone : +390659784737
Email : p.folino@aifa.gov.it
One hundred thousand medicinal products are licensed in the European countries and tons of medicines are daily used with a yearly expenditure wider than 100 billion euro. The reasons for creating this EUPHA section on utilisation of medicines were :
The aims of this section are:
The EUPHA section on the utilisation of medicines is presided by Dr. Pietro Folino-Gallo from the Italian Medicines Agency, Rome, Italy and Professor Arne Melander from the NEPI Foundation and Malmo University Hospital, Sweden. The section currently has 150 members. Members of the section are also involved in two European Union-funded projects: EURO-MED-STAT and PPRI. EURO-MED-STAT is a project devoted to build a database of medicines available in Europe with information on their price, utilisation and expenditure. Moreover an inventory of the e-prescribing database in European countries is ongoing with the aim to evaluate the possibility to pool together data from the inventoried sources in a “European Primary Care Database”. The PPRI project aims to produce a country profile, according to an established template, for each participating country.
In 2006, the section has contributed to the publication of two special issues of the Italian Journal of Public Health: the first one devoted to medical errors, with special regard to medication errors and safety; the second one devoted to medicine utilisation and public health.
In 2007 the section “Utilisation of medicines” has organised a workshop within the EUPHA Conference in Helsinki presenting and discussing some data mainly related to dispensing and reimbursement flow (as collected by the EURO-MED-STAT project) and prescribing data (from GP database as evaluated from the electronic Health Indicator Data project) using diabetes as a test case.
By its members the section is present in several EU activities including the Working party on health care systems (DG Public Health) and the Working Group on pricing of the Pharmaceutical Forum (DG Industry and Public Health).